Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP
1725 results:
1. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
2. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
3. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract] [Full Text] [Related]
4. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
Dall CP; Mason JB; Goldman CC; Fabrizio G; Alagha EC; Chou J; Kowalczyk KJ; Agarwal PK; Stamatakis L; Krasnow RE
Urol Oncol; 2024 May; 42(5):121-132. PubMed ID: 38418269
[TBL] [Abstract] [Full Text] [Related]
5. Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience".
Naim A; Lahlou Z; Kaanouch O; Heddat A; Mansouri S
Arch Ital Urol Androl; 2024 Feb; 96(1):12104. PubMed ID: 38363238
[TBL] [Abstract] [Full Text] [Related]
6. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract] [Full Text] [Related]
7. Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy.
Stanford SM; Nguyen TP; Chang J; Zhao Z; Hackman GL; Santelli E; Sanders CM; Katiki M; Dondossola E; Brauer BL; Diaz MA; Zhan Y; Ramsey SH; Watson PA; Sankaran B; Paindelli C; Parietti V; Mikos AG; Lodi A; Bagrodia A; Elliott A; McKay RR; Murali R; Tiziani S; Kettenbach AN; Bottini N
Sci Adv; 2024 Feb; 10(5):eadg7887. PubMed ID: 38295166
[TBL] [Abstract] [Full Text] [Related]
8. The Ability of the STAR-cap Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
9. Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET.
Huebner NA; Wasinger G; Rajwa P; Resch I; Korn S; Rasul S; Baltzer P; Prüger L; Rauschmeier A; Seitz C; Comperat E; Shariat SF; Grubmüller B
Urol Oncol; 2024 Apr; 42(4):115.e9-115.e16. PubMed ID: 38246806
[TBL] [Abstract] [Full Text] [Related]
10. Surgeon seniority and experience have no effect on cap detection rates using MRI/TRUS fusion-guided targeted biopsies.
Taha F; Larre S; Branchu B;
Urol Oncol; 2024 Mar; 42(3):67.e1-67.e7. PubMed ID: 38245408
[TBL] [Abstract] [Full Text] [Related]
11. Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer.
Sidana A; Tayebi S; Blank F; Lama DJ; Meyer M; Saeed Y; Tobler J; Hsu WW; Verma S
Urol Oncol; 2024 May; 42(5):158.e1-158.e10. PubMed ID: 38245407
[TBL] [Abstract] [Full Text] [Related]
12. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy.
Wang B; Fu Y; Chen M; Peng S; Marra G; Zhuang J; Zhang S; Guo H; Qiu X
Urol Oncol; 2024 Mar; 42(3):67.e9-67.e15. PubMed ID: 38233262
[TBL] [Abstract] [Full Text] [Related]
13. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract] [Full Text] [Related]
14. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.
Smani S; Novosel M; Sutherland R; Jeong F; Jalfon M; Marks V; Rajwa P; Nolazco JI; Washington SL; Renzulli JF; Sprenkle P; Kim IY; Leapman MS
Urol Oncol; 2024 Feb; 42(2):28.e9-28.e20. PubMed ID: 38161105
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of Novel Inhibitors of brd4 for Treating prostate cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design.
Zhong H; Wang X; Chen S; Wang Z; Wang H; Xu L; Hou T; Yao X; Li D; Pan P
J Med Chem; 2024 Jan; 67(1):138-151. PubMed ID: 38153295
[TBL] [Abstract] [Full Text] [Related]
16. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP
Oncogene; 2024 Feb; 43(7):484-494. PubMed ID: 38135694
[TBL] [Abstract] [Full Text] [Related]
17. Performance of cognitive vs. image-guided fusion biopsy for detection of overall and clinically significant prostate cancer in a multiethnic population.
Ho K; Zhu D; Gupta K; Loloi J; Abramson M; Watts K; Agalliu I; Sankin A
Urol Oncol; 2024 Feb; 42(2):29.e1-29.e8. PubMed ID: 38114350
[TBL] [Abstract] [Full Text] [Related]
18. Integrative bioinformatics analysis of biomarkers and pathways for exploring the mechanisms and molecular targets associated with pyroptosis in type 2 diabetes mellitus.
Wang W; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1207142. PubMed ID: 38034011
[TBL] [Abstract] [Full Text] [Related]
19. Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with prostate cancer under Androgen Deprivation Therapy.
Mafla-España MA; Torregrosa MD; Beamud-Cortés M; Bermell-Marco L; Rubio-Briones J; Cauli O
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002324
[TBL] [Abstract] [Full Text] [Related]
20. Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in prostate cancer.
Liang H; Yang C; Zeng R; Song Y; Wang J; Xiong W; Yan B; Jin X
Adv Sci (Weinh); 2023 Dec; 10(36):e2302368. PubMed ID: 37949681
[TBL] [Abstract] [Full Text] [Related]
[Next]
